Hadassah

Clinical Trial at Hadassah Hospital Yields Positive Results With Noninvasive Test for Liver Cancer

Monday, Oct 24 2011

A clinical trial conducted at the Hadassah University Medical Center has revealed that BreathID, a new noninvasive device for the detection of hepato-cellular carcinoma, a type of liver cancer, achieved diagnostic results similar to CT Scans and MRIs. BreathID was developed by Exalenz Bioscience Ltd., whose Medical Director is Prof. Yaron Ilan, Director of Hadassah's Department of Internal Medicine.

The 36 patients in the trial were first checked by ultrasound; those suspected to have liver cancer underwent a CT Scan or MRI, which revealed that 26 patients had the disease. All the patients were then given breath tests with the BreathID device to determine whether it could achieve similar statistically meaningful results. The device achieved a congruence of 93 percent. Exalenz now plans to begin a larger trial of the device, which will involve 100 patients at five hospitals in Israel, the United States, and Canada.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›
alt_text

Tuesday, Apr 17 2018

Predicting Clinical Outcomes for Multiple Sclerosis Patients: Cutting-Edge Research at Hadassah

More than two million people--two to three times more women--have multiple sclerosis (MS)--the leading cause of neurological disability among young adults. What is their prognosis?

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More